MedPath

Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy

Conditions
Peripheral Neuropathy
Registration Number
NCT01524666
Lead Sponsor
JFK Medical Center
Brief Summary

This is a nonblinded Case-only study that evaluates the effects of Agmatine Sulfate on small fiber peripheral neuropathy. Patients will be started on Agmatine sulfate (a metabolite of Arginine) and monitored for two months. Improvement will be noted on their response to the Neuropathic Pain Questionnaire. Additionally the investigators will note improvement by performing autonomic function testing at the beginning and end of the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Men and Women Ages 18-75 with symptoms of small Fiber Neuropathy and have been diagnosed via autonomic function testing and or skin biopsy
Exclusion Criteria
  • Women who are pregnant or breast feeding, patients with history of substance abuse, and patients with myelopathy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Neuropathic Pain QuestionnaireAfter 2 months
Secondary Outcome Measures
NameTimeMethod
QSART & ANSAR testingAfter 2 months

Trial Locations

Locations (1)

JFK Medical Center

πŸ‡ΊπŸ‡Έ

Edison, New Jersey, United States

JFK Medical Center
πŸ‡ΊπŸ‡ΈEdison, New Jersey, United States
Michael D Rosenberg, M.D.
Contact
732-321-7010
MRosenberg@JFKHealth.org

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.